AU2014373588B2 - Genetic markers associated with suicide risk and methods of use thereof - Google Patents

Genetic markers associated with suicide risk and methods of use thereof Download PDF

Info

Publication number
AU2014373588B2
AU2014373588B2 AU2014373588A AU2014373588A AU2014373588B2 AU 2014373588 B2 AU2014373588 B2 AU 2014373588B2 AU 2014373588 A AU2014373588 A AU 2014373588A AU 2014373588 A AU2014373588 A AU 2014373588A AU 2014373588 B2 AU2014373588 B2 AU 2014373588B2
Authority
AU
Australia
Prior art keywords
subject
suicide
seq
marker
allele
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014373588A
Other languages
English (en)
Other versions
AU2014373588A1 (en
Inventor
James L. Kennedy
Clement C. Zai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre for Addiction and Mental Health
Original Assignee
Centre for Addiction and Mental Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre for Addiction and Mental Health filed Critical Centre for Addiction and Mental Health
Publication of AU2014373588A1 publication Critical patent/AU2014373588A1/en
Application granted granted Critical
Publication of AU2014373588B2 publication Critical patent/AU2014373588B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G16B30/10—Sequence alignment; Homology search
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C99/00—Subject matter not provided for in other groups of this subclass
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Data Mining & Analysis (AREA)
  • Primary Health Care (AREA)
  • Epidemiology (AREA)
AU2014373588A 2013-12-23 2014-12-23 Genetic markers associated with suicide risk and methods of use thereof Ceased AU2014373588B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361920332P 2013-12-23 2013-12-23
US61/920,332 2013-12-23
PCT/CA2014/051257 WO2015095967A1 (en) 2013-12-23 2014-12-23 Genetic markers associated with suicide risk and methods of use thereof

Publications (2)

Publication Number Publication Date
AU2014373588A1 AU2014373588A1 (en) 2016-07-21
AU2014373588B2 true AU2014373588B2 (en) 2021-04-01

Family

ID=53477254

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014373588A Ceased AU2014373588B2 (en) 2013-12-23 2014-12-23 Genetic markers associated with suicide risk and methods of use thereof

Country Status (10)

Country Link
US (1) US10435748B2 (https=)
EP (1) EP3087203B1 (https=)
JP (1) JP6679486B2 (https=)
KR (1) KR20160111925A (https=)
CN (1) CN106062213A (https=)
AU (1) AU2014373588B2 (https=)
CA (1) CA2934815C (https=)
IL (1) IL246417B (https=)
SG (1) SG11201605150YA (https=)
WO (1) WO2015095967A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2891830A1 (en) 2015-05-15 2016-11-15 Centre For Addiction And Mental Health Genetic markers for suicide risk and related methods
JP2019520315A (ja) * 2016-04-29 2019-07-18 スパーナス ファーマシューティカルズ インコーポレイテッド 衝動的攻撃性を監視、診断、及び治療する方法、システム、及びキット
CN108531569B (zh) * 2017-03-03 2021-05-07 上海伯豪医学检验所有限公司 用于强迫症与精神分裂症、抑郁症甄别的基因标志物及其应用
CN108148905A (zh) * 2018-02-13 2018-06-12 广州市番禺区中心医院(广州市番禺区人民医院、广州市番禺区心血管疾病研究所) 一段可作为抑郁症标记物的序列
WO2020235721A1 (ko) * 2019-05-23 2020-11-26 울산과학기술원 다중 오믹스 분석을 이용한 우울증 또는 자살 위험 예측용 마커 발굴 방법, 우울증 또는 자살 위험 예측용 마커, 및 다중 오믹스 분석을 이용한 우울증 또는 자살 위험 예측 방법
WO2024215722A1 (en) * 2023-04-10 2024-10-17 Board Of Regents, The University Of Texas System Methods and compositions for diagnosing and treating depression and suicide risk

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2166112A1 (en) * 2008-09-18 2010-03-24 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Means and methods for diagnosing predisposition for treatment emergent suicidal ideation (TESI)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USH2191H1 (en) * 2000-10-24 2007-06-05 Snp Consortium Identification and mapping of single nucleotide polymorphisms in the human genome
US7361468B2 (en) * 2004-07-02 2008-04-22 Affymetrix, Inc. Methods for genotyping polymorphisms in humans
US20120094855A1 (en) * 2008-09-18 2012-04-19 Max Planck Society Means and methods for diagnosing predisposition for treatment emergent suicidal ideation (tesi)
KR101249635B1 (ko) * 2010-10-13 2013-04-01 서울대학교산학협력단 양극성 장애 진단용 ｅｇｒ2 유전자 ｓｎｐ, 그를 포함하는 마이크로어레이 및 키트

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2166112A1 (en) * 2008-09-18 2010-03-24 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Means and methods for diagnosing predisposition for treatment emergent suicidal ideation (TESI)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WILLOUR VL ET AL., "A Genome-Wide Association Study of Attempted Suicide", MOL PSYCHIATRY, (April 2012), vol. 17, no. 4, pages 433 - 444 *

Also Published As

Publication number Publication date
EP3087203A1 (en) 2016-11-02
US20170002412A1 (en) 2017-01-05
CA2934815A1 (en) 2015-07-02
EP3087203A4 (en) 2017-09-20
WO2015095967A1 (en) 2015-07-02
SG11201605150YA (en) 2016-07-28
CN106062213A (zh) 2016-10-26
CA2934815C (en) 2022-01-04
KR20160111925A (ko) 2016-09-27
AU2014373588A1 (en) 2016-07-21
JP2017503493A (ja) 2017-02-02
US10435748B2 (en) 2019-10-08
IL246417B (en) 2020-08-31
IL246417A0 (en) 2016-08-31
EP3087203B1 (en) 2019-09-11
JP6679486B2 (ja) 2020-04-15

Similar Documents

Publication Publication Date Title
AU2014373588B2 (en) Genetic markers associated with suicide risk and methods of use thereof
Smith et al. Multiple regulatory variants modulate expression of 5-hydroxytryptamine 2A receptors in human cortex
JP7701419B2 (ja) バイオマーカー
KR102158717B1 (ko) Cd163l1 유전자의 단일염기다형성을 포함하는 뇌동맥류 진단용 snp 마커
KR102158716B1 (ko) Arhgap32 유전자의 단일염기다형성을 포함하는 뇌동맥류 진단용 snp 마커
Cossée et al. Exonic microdeletions in the X-linked PQBP1 gene in mentally retarded patients: a pathogenic mutation and in-frame deletions of uncertain effect
KR102158713B1 (ko) Gba 유전자의 단일염기다형성을 포함하는 뇌동맥류 진단용 snp 마커
KR102158721B1 (ko) Rnf144a 유전자의 단일염기다형성을 포함하는 뇌동맥류 진단용 snp 마커
US10301678B2 (en) Genetic markers for antipsychotic induced weight gain and methods for use thereof
US20230220472A1 (en) Deterimining risk of spontaneous coronary artery dissection and myocardial infarction and sysems and methods of use thereof
KR102158715B1 (ko) Olfml2a 유전자의 단일염기다형성을 포함하는 뇌동맥류 진단용 snp 마커
US20100129805A1 (en) Slc1a1 antipsychotic drug response markers
KR20220025985A (ko) 만성 감각신경성 이명 진단용 snp 마커 및 이를 이용한 진단 방법
Kerkfeld et al. Genomic aspects for the diagnosis of craniofacial disorders
KR102752009B1 (ko) 비번역 RNA의 rs56823384 SNP를 포함하는 지주막하 출혈 예후 예측용 마커
KR102158719B1 (ko) Loc102724084 유전자의 단일염기다형성을 포함하는 뇌동맥류 진단용 snp 마커
KR102158723B1 (ko) Spcs3 유전자의 단일염기다형성을 포함하는 뇌동맥류 진단용 snp 마커
KR102158725B1 (ko) Mink1 유전자의 단일염기다형성을 포함하는 뇌동맥류 진단용 snp 마커
KR102158722B1 (ko) Flj45964 유전자의 단일염기다형성을 포함하는 뇌동맥류 진단용 snp 마커
KR102158720B1 (ko) Lrrc3 유전자의 단일염기다형성을 포함하는 뇌동맥류 진단용 snp 마커
KR102158714B1 (ko) Tcf24 유전자의 단일염기다형성을 포함하는 뇌동맥류 진단용 snp 마커
KR102158724B1 (ko) Lingo2 유전자의 단일염기다형성을 포함하는 뇌동맥류 진단용 snp 마커
KR102158718B1 (ko) Cul4a 유전자의 단일염기다형성을 포함하는 뇌동맥류 진단용 snp 마커
KR20260039156A (ko) 뇌전증 진단용 조성물
Bergen et al. Summaries from the XVIII World Congress of Psychiatric Genetics, Athens, Greece, 3–7 October 2010

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired